On Tuesday, Ascendis Pharma A/S ADR (NASDAQ: ASND) opened lower -4.63% from the last session, before settling in for the closing price of $170.74. Price fluctuations for ASND have ranged from $111.09 to $183.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 185.30%. Company’s average yearly earnings per share was noted 35.93% at the time writing. With a float of $59.90 million, this company’s outstanding shares have now reached $60.37 million.
In terms of profitability, gross margin is 85.3%, operating margin of -90.54%, and the pretax margin is -91.75%.
Ascendis Pharma A/S ADR (ASND) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ascendis Pharma A/S ADR is 0.78%, while institutional ownership is 105.51%. The most recent insider transaction that took place on May 06 ’25, was worth 1,700,485. Before that another transaction happened on May 05 ’25, when Company’s Officer proposed sale 4,386 for $170.99, making the entire transaction worth $749,948.
Ascendis Pharma A/S ADR (ASND) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 35.93% per share during the next fiscal year.
Ascendis Pharma A/S ADR (NASDAQ: ASND) Trading Performance Indicators
Check out the current performance indicators for Ascendis Pharma A/S ADR (ASND). In the past quarter, the stock posted a quick ratio of 0.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 24.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.29, a number that is poised to hit -1.55 in the next quarter and is forecasted to reach 1.86 in one year’s time.
Technical Analysis of Ascendis Pharma A/S ADR (ASND)
Compared to the last year’s volume of 0.52 million, its volume of 0.75 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 48.42%. Additionally, its Average True Range was 8.67.
During the past 100 days, Ascendis Pharma A/S ADR’s (ASND) raw stochastic average was set at 68.97%, which indicates a significant increase from 34.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.44% in the past 14 days, which was lower than the 48.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $156.21, while its 200-day Moving Average is $138.84. Nevertheless, the first resistance level for the watch stands at $168.94 in the near term. At $175.05, the stock is likely to face the second major resistance level. The third major resistance level sits at $178.63. If the price goes on to break the first support level at $159.25, it is likely to go to the next support level at $155.67. Now, if the price goes above the second support level, the third support stands at $149.56.
Ascendis Pharma A/S ADR (NASDAQ: ASND) Key Stats
There are currently 60,971K shares outstanding in the company with a market cap of 9.83 billion. Presently, the company’s annual sales total 393,500 K according to its annual income of -409,120 K. Last quarter, the company’s sales amounted to 106,360 K and its income totaled -99,690 K.
